Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Isotope & RadiationFRA:5IR +1.14%92 EV-to-EBIT is 7.47 as of Aug. 28, 2026, which is 33% above its 10-year median of 5.61. GuruFocus rates FRA:5IR with a GF Score™ of 92/100 and a GF Value™ of €1.63. The stock has 5 warning signs investors should review. Among 480 Medical Devices & Instruments companies, China Isotope & Radiation ranks better than 83.75% on this metric.
The historical rank and industry rank for China Isotope & Radiation's EV-to-EBIT or its related term are showing as below:
FRA:5IR'
s EV-to-EBIT Range Over the Past 10 Years
Min: 2.92 Med: 5.61 Max: 13.31
Current: 7.51
During the past 11 years, the highest EV-to-EBIT of China Isotope & Radiation was 13.31. The lowest was 2.92. And the median was 5.61.
FRA:5IR's EV-to-EBIT is ranked better than 83.75% of 480
companies
in the Medical Devices & Instruments industry
Industry Median: 18.86
vs FRA:5IR: 7.51
China Isotope & Radiation (FRA:5IR) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
China Isotope & Radiation's Enterprise Value for the quarter that ended in Dec. 2025 was €1,043.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Isotope & Radiation's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €129.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Isotope & Radiation EV-to-EBIT Related Terms
China Isotope & Radiation EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, China Isotope & Radiation's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Isotope & Radiation EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where China Isotope & Radiation's EV-to-EBIT falls into.
China Isotope & Radiation's current Enterprise Value is €966.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Isotope & Radiation's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €129.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Isotope & Radiation (FRA:5IR) has a EV-to-EBIT of 7.47 as of Aug. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on China Isotope & Radiation and its competitors. This is 33% above median its historical median of 5.61. Over the past decade, China Isotope & Radiation's EV-to-EBIT has ranged from 2.92 to 13.31. According to the industry distribution chart, China Isotope & Radiation ranks #78 out of 480 companies in the Medical Devices & Instruments industry, placing it in the top 16.2%.
Is China Isotope & Radiation's EV-to-EBIT too high?
China Isotope & Radiation's current EV-to-EBIT of 7.47 is 33% above median its 10-year median of 5.61. Over the past 10 years, this metric has ranged from a low of 2.92 to a high of 13.31. The Medical Devices & Instruments industry median EV-to-EBIT is 18.86. China Isotope & Radiation's value of 7.47 is 60.4% below this industry median. Based on the distribution chart, China Isotope & Radiation ranks #78 out of 480 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, China Isotope & Radiation has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Isotope & Radiation's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, China Isotope & Radiation ranks #78 out of 480 companies for EV-to-EBIT. This places China Isotope & Radiation in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.86. China Isotope & Radiation's value of 7.47 is 60.4% below this benchmark. Historically, China Isotope & Radiation's own EV-to-EBIT has ranged from 2.92 to 13.31 over the past decade. While the company's 10-year median is 5.61 vs. the industry median of 18.86, China Isotope & Radiation has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.86, based on 480 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Isotope & Radiation's current EV-to-EBIT of 7.47 is 60.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on China Isotope & Radiation and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Isotope & Radiation's current EV-to-EBIT is 7.47, which is 33% above median its own 10-year median of 5.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Isotope & Radiation stock overvalued right now?
China Isotope & Radiation (FRA:5IR) has a current EV-to-EBIT of 7.47. The stock's GF Value™ is €1.63, compared to a current price of €1.77 — trading 8.6% above its estimated fair value. The current EV-to-EBIT is 7.47, which is 33% above median its 10-year median of 5.61 and 60.4% below the Medical Devices & Instruments industry median of 18.86. China Isotope & Radiation's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For China Isotope & Radiation (FRA:5IR), the current EV-to-EBIT is 7.47 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Isotope & Radiation (FRA:5IR) Overvalued in 2026?
Based on GuruFocus' analysis, China Isotope & Radiation stock appears to be overvalued.
The current stock price of €1.77 is trading 8.6% above its estimated GF Value™ of €1.63.
Key valuation signals for FRA:5IR:
EV-to-EBIT: 7.47 (33% above median its 10-year median of 5.61)
GF Value™: €1.63 vs. price of €1.77 (8.6% above fair value)
Industry Position: 60.4% below the Medical Devices & Instruments median (#78 of 480)
No single metric tells the full story. See the FRA:5IR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: (1) nuclear medicine; (2) radioactive source products; (3) irradiation; (4) nuclear medical equipment and related services; and (5) other businesses. Nuclear medicines: manufacturing and sale of a range of imaging diagnostic and therapeutic radio pharmaceuticals imaging, UBT diagnostic kits and test analysers and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The company's operations are carried out and a majority of its customers are located in the PRC.
92GF Score
Get the complete analysis for FRA:5IR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5IR has been successfully added to your 
